Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Masitinib, AB Science's lead product, is an oral tyrosine kinase inhibitor that specifically targets innate immunity of MS patients. Masitinib at a dose of 4.5 mg/kg/day slowed disease progression in patients, which was the study’s primary objective.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
The current research provides evidence suggesting that masitinib’s therapeutic efficacy is associated with a synapto-protective action in relation with mast cells inhibition.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
Study AB19001 is an international Phase 3 study to compare the efficacy and safety of masitinib in combination with riluzole vs placebo in combination with riluzole in ALS.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Biotin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
Details:
SPI2 was designed to confirm the results of the first positive Phase III study, MS-SPI, in progressive multiple sclerosis (MS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
Details:
Masitinib significantly delays disability progression on EDSS in patients with primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
